eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2014
vol. 39
 
Share:
Share:
abstract:

Experimental immunology
A novel peptide from TCTA protein inhibits proliferation of fibroblast-like synoviocytes of rheumatoid arthritis patients

Yuki Nanke
,
Toru Yago
,
Tsuyoshi Kobashigawa
,
Manabu Kawamoto
,
Hisashi Yamanaka
,
Shigeru Kotake

(Centr Eur J Immunol 2014; 39 (4): 468-470)
Online publish date: 2014/12/15
View full text Get citation
 
PlumX metrics:
Background: We have demonstrated that a peptide, which we named ‘Peptide A’, derived from the extracellular domain of T-cell leukemia translocation-associated gene (TCTA) protein, inhibited human osteoclastogenesis.

Objective: In the current study, we examined whether this peptide inhibits the proliferation of rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) or not.

Material and methods: Fibroblast-like synoviocytes obtained from five RA patients were cultured in the absence or presence of 1, 5, 10 µg/ml of peptide. We used 29-mer scrambled peptide as a control.

Results: The peptide inhibited the proliferation of RA FLS dose-dependently. On the other hand, the scrambled peptide showed no inhibition.

Conclusions: The peptide inhibits both human osteoclastogenesis and the proliferation of RA FLS. Thus, the peptide may be used for the therapy of both osteoporosis and synovitis of RA patients.

This is the first report of the new peptide we discovered, which inhibits both osteoclastogenesis and synovitis. Thus, this new peptide could be a new drug for patients with both osteoporosis and RA.
keywords:

osteoclast, arthritis, synovium, translocation-associated gene (TCTA), T-cell leukemia

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.